<DOC>
	<DOCNO>NCT01066546</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability dimebon subject moderate-to-severe Alzheimer 's Disease .</brief_summary>
	<brief_title>An Extension To The B1451006 Protocol To Evaluate The Safety Efficacy Dimebon In Subjects With Moderate-to-Severe Alzheimer 's Disease</brief_title>
	<detailed_description>This study terminate May 7 , 2010 due modification dimebon development plan , follow lack demonstration efficacy complete DIM14 ( CONNECTION ) Study . The study terminate due safety finding . Dimebon well-tolerated clinical trial . Demonstration efficacy dimebon Alzheimer 's disease pending completion ongoing DIM18 ( CONCERT ) Study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion 6 month treatment previous B1451006 Phase 3 dimebon study Any major medical illness unstable medical condition may increase risk associate study participation investigational product administration may interfere ability interpret study safety data</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Delirium</keyword>
	<keyword>Dementia</keyword>
	<keyword>Amnestic</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
</DOC>